HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech (NASDAQ:EVAX) and maintained a $14 price target.
August 01, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech and maintained a $14 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. suggests strong confidence in Evaxion Biotech's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100